Capecitabine in the management of colorectal cancer
Bradford R Hirsch, S Yousuf ZafarDivision of Medical Oncology, Duke University Medical Center, Durham, NC, USAAbstract: 5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly five decades; however, the use of oral formulations of the medication has been gaining increasin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-03-01
|
| Series: | Cancer Management and Research |
| Online Access: | http://www.dovepress.com/capecitabine-in-the-management-of-colorectal-cancer-a6831 |
| _version_ | 1818968864772325376 |
|---|---|
| author | Hirsch BR Zafar SY |
| author_facet | Hirsch BR Zafar SY |
| author_sort | Hirsch BR |
| collection | DOAJ |
| description | Bradford R Hirsch, S Yousuf ZafarDivision of Medical Oncology, Duke University Medical Center, Durham, NC, USAAbstract: 5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly five decades; however, the use of oral formulations of the medication has been gaining increasing traction since capecitabine was approved for use in adjuvant settings by the US Food and Drug Administration in 2005. The use of capecitabine has since spread to a number of off-label indications, including the treatment of advanced or metastatic colorectal cancer and the neoadjuvant treatment of rectal cancer. In light of increasing utilization, it is critical that clinicians have a firm understanding of the literature supporting capecitabine across various settings as well as the attributes of the drug, such as its dosing recommendations, side-effect profile, and use in the elderly. The purpose of this review is to synthesize the literature in a fashion that can be used to help guide decisions. In a setting of increasing focus on cost, the pharmacoeconomic literature is also briefly reviewed.Keywords: colon cancer, colorectal cancer, rectal cancer, capecitabine, Xeloda |
| first_indexed | 2024-12-20T14:11:28Z |
| format | Article |
| id | doaj.art-c78987580bd6453d9a56001595f306fe |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-20T14:11:28Z |
| publishDate | 2011-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-c78987580bd6453d9a56001595f306fe2022-12-21T19:38:07ZengDove Medical PressCancer Management and Research1179-13222011-03-012011default79896831Capecitabine in the management of colorectal cancerHirsch BRZafar SYBradford R Hirsch, S Yousuf ZafarDivision of Medical Oncology, Duke University Medical Center, Durham, NC, USAAbstract: 5-Fluorouracil has been a mainstay in the treatment of colorectal cancer for nearly five decades; however, the use of oral formulations of the medication has been gaining increasing traction since capecitabine was approved for use in adjuvant settings by the US Food and Drug Administration in 2005. The use of capecitabine has since spread to a number of off-label indications, including the treatment of advanced or metastatic colorectal cancer and the neoadjuvant treatment of rectal cancer. In light of increasing utilization, it is critical that clinicians have a firm understanding of the literature supporting capecitabine across various settings as well as the attributes of the drug, such as its dosing recommendations, side-effect profile, and use in the elderly. The purpose of this review is to synthesize the literature in a fashion that can be used to help guide decisions. In a setting of increasing focus on cost, the pharmacoeconomic literature is also briefly reviewed.Keywords: colon cancer, colorectal cancer, rectal cancer, capecitabine, Xelodahttp://www.dovepress.com/capecitabine-in-the-management-of-colorectal-cancer-a6831 |
| spellingShingle | Hirsch BR Zafar SY Capecitabine in the management of colorectal cancer Cancer Management and Research |
| title | Capecitabine in the management of colorectal cancer |
| title_full | Capecitabine in the management of colorectal cancer |
| title_fullStr | Capecitabine in the management of colorectal cancer |
| title_full_unstemmed | Capecitabine in the management of colorectal cancer |
| title_short | Capecitabine in the management of colorectal cancer |
| title_sort | capecitabine in the management of colorectal cancer |
| url | http://www.dovepress.com/capecitabine-in-the-management-of-colorectal-cancer-a6831 |
| work_keys_str_mv | AT hirschbr capecitabineinthemanagementofcolorectalcancer AT zafarsy capecitabineinthemanagementofcolorectalcancer |